Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00240643 · ClinicalTrials.gov registry record · Phase 2
Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 640
- Enrollment target
NCT00240643 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 640 participants.
The verdict
NCT00240643, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 640 participants
- Enrollment target
Study Summary
This study will allow determination of the pharmacokinetic and pharmacodynamics of SB424323 in a relevant population. The data from this study will be used along with other data to aid in choosing the most appropriate dose for the later phase study.
Interventions
- DRUG SB424323
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 640 participants |
| Start Date | 2005-11 |
| Est. Completion | 2006-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00240643
The ClinicalTrials.gov registry entry for NCT00240643 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 640 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SB424323 is the first listed.
NCT00240643 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00240643 about?
NCT00240643 is a clinical study titled "Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke". This study will allow determination of the pharmacokinetic and pharmacodynamics of SB424323 in a relevant population. The data from this study will be used along with other data to aid in choosing the most appropriate dose for the later phase study.
What is the current status of trial NCT00240643?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 640 participants. The study started on 2005-11. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00240643?
The interventions under investigation include: SB424323 (DRUG).
Who is sponsoring clinical trial NCT00240643?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.